Nrf2 activation for kidney disease treatment—a mixed blessing?

Masahiro Nezu, Norio Suzuki

Research output: Contribution to journalComment/debate

4 Citations (Scopus)


Activation of cellular antioxidative signaling is expected to be a silver bullet against kidney diseases, and clinical trials of compounds activating the antioxidant transcription factor Nrf2 have revealed their renoprotective effects. However, cardiac events have been observed in some cases with elevated urinary albumin excretion in these trials. Therefore, elucidating the negative effects of Nrf2 activation is essential. Rush and colleagues demonstrated that Nrf2 activation aggravates podocyte injury, a factor related to proteinuria and cardiac failure.

Original languageEnglish
Pages (from-to)20-22
Number of pages3
JournalKidney International
Issue number1
Publication statusPublished - 2021 Jan


Dive into the research topics of 'Nrf2 activation for kidney disease treatment—a mixed blessing?'. Together they form a unique fingerprint.

Cite this